Proviva Pharma Journey from the Start
Our story starts in Montreal, Quebec, the most vibrant Canadian city and a global leader in technology, pharmaceuticals, artificial intelligence and more!
To share our story more clearly, let us tell you more about our company and our team.
Our Path and Goal
We’ve established a number of national and international collaborations in order to understand the health needs of people world-wide. Our goal is to revolutionize the global health industry with novel microbiome, probiotics and other health products. To accomplish this, we are engaged in:
Developing and marketing innovative probiotics for heart health, gastrointestinal diseases, bone, obesity, metabolic disease and others.
Understanding the role of microbiome in health and diseases and focused on human and livestock health through the microbiome.
Stimulating healthy living and promoting active life, aging and longevity through microbiome.
Pushing the limits of understanding health in research and manufacturing sectors.
Offering next-generation therapeutics that are active, effective and affordable.
Working in collaboration with global partnerships in research, manufacturing and distribution of our current and future products.
Our Vision and Our Mission
Building a healthy environment that supports development for the community and people
Our mission is to develop and distribute the most effective means for healthy living by re-establishing the balance of the gastrointestinal microflora.
Today’s diet and lifestyle has greatly reduced the complexity of our gut microflora as increasing populations of pathogenic bacteria are feeding on the over-consumed simple sugars at the expense of fiber-feeding probiotic bacteria. This imbalance rears several whole-body physiological imbalances that ultimately lead to disease development:
To succeed at our mission we took the following approaches:
Whole-body health :
At Proviva Pharma, we believe that a healthy constitution begins in the gastrointestinal tract. Hence, it is our vision to develop ways to heal whole-body chronic diseases by re-establishing a healthy homeostasis in the gastrointestinal microflora.
Advance medical paradigms :
We seek to advance the modern medical paradigm of disease development by understanding the mechanisms of microflora-derived communication with the host. By implementing these mechanisms, we will evolve aspects of the gut microflora and their host-communication as therapeutic targets for disease.
Alleviate chronic disease :
The influence of gastrointestinal health reaches much further than our intestines. A healthy microflora impacts cardiovascular health, cancer development, neurological health, the development and integrity of our immune system, bone health and virtually every aspect of our longevity and healthy aging. Currently, it is accepted that a healthy gut is imperative to maintain overall vitality, but the power of utilizing the gut microflora as a preventative and therapeutic agent is still relatively untapped. At Proviva Pharma, we seek to realize the potential of our microscopic gastrointestinal inhabitants in healing chronic diseases.
Our Research in the Media
On Jun 16, 2018, The Canadian Newspaper wrote about our research with the headline, “GUT INSTINCT Could taking this supplement and Indian herbal remedy help you live to 100? Combination could boost your lifespan, new study finds. The combination was found to boost a fruit fly’s lifespan by 60%“
Proviva Pharma Management
Dr. Hongmei Chen
Director, Business Development Asia
Dr. Hongmei Chen completed her education in China (BSc and MS) and in Canada (PhD). She also had postdoctoral training in tissue repair and regeneration. Her previous R&D experiences in biomedical engineering are extensive, covering biomaterials, drug delivery, human microbiome and probiotics, artificial cells and cell therapy and tissue engineering. Hongmei has produced a large number of high impactful publications; some of her findings were highly recognized in the academic community and translated to clinical products. Hongmei has also won a number of prestigious awards.
Chief Executive officer
John Probandt has over thirty (30) years of experience investing in fitness, health, nutrition, diet, and bioscience industries. He was the youngest Senior Vice President in the history of San Francisco-based Dean Witter Reynolds, which later was acquired by Morgan Stanley. He is responsible for the completion with investing over three hundred million USD (300,000,000.00) in privately held health-related enterprises. In addition, he has been responsible for the deployment of well over two and a half billion dollars USD (2,500,000,000.00) in publicly traded health sector opportunities. He has a deep passion for helping people enjoy a long and healthy life. Mr. Probandt has been an owner, investor and innovator within the health, nutrition, diet, and fitness industries for over three decades. John is also President of BFD diet.
prof. Satya Prakash
Dr. Prakash is founder of Proviva Pharm and Professor of Biomedical Engineering, Artificial Cells and Organs, Physiology, Experimental Medicine and Surgery in the Faculty of Medicine, at McGill University, Montreal, Quebec, Canada. Dr. Prakash is co-founder of Micropharma and MangoGen Pharma. He has contributed to the advancement and understanding of the human microbiome, probiotic formulations for use in neurological disorders such as Alzheimer’s, Parkinson’s, aging, metabolic syndrome, obesity, cardiovascular diseases, medical devices such as next generation of stents, film dressing and targeted delivery of drugs, live cells, and therapeutic molecules. Dr. Prakash is the leading author of more than 350 research papers/abstracts and several book chapters, research, and other scholarly articles. His publication list includes 72 approved/pending patents and 3 edited books. He is also the winner of more than 30 international awards including “Medial for Outstanding Contribution to the Advancement of Science”, Fraser, Monat and McPherson Award, Canadian Institute of Health Research Investigator Award, and FRSQ Chercheure‐Boursière, Shandong China.